Mean ± standard deviation or n (%) Vildagliptin 50 mg qd (N = 122) Placebo (N = 89) Vildagliptin 50 mg qd (N = 94) Placebo (N = 64)
Demographic variable
Age (years) 67.1 ± 9.0 69.3 ± 7.2 63.7 ± 9.1 65.4 ± 10.5
eGFR [MDRD (ml/min/1.732)] 39.5 ± 6.0 40.2 ± 5.6 22.3 ± 5.6 21.0 ± 6.4
Age group n (%)
≥65 years 81 (66.4) 70 (78.7) 45 (47.9) 34 (53.1)
≥75 years 24 (19.7) 20 (22.5) 11 (11.7) 14 (21.9)
Sex male 70 (57.4) 55 (61.8) 49 (52.1) 33 (51.6)
Race
Europid 83 (68.0) 62 (69.7) 45 (47.9) 36 (56.3)
Asian (Indian subcontinent) 15 (12.3) 12 (13.5) 15 (46.0) 11 (17.2)
Asian (non-Indian subcontinent) 0 (0.0) 0 (0.0) 2 (2.1) 0 (0.0)
Hispanic or latino 21 (17.2) 12 (13.5) 29 (30.9) 17 (26.6)
Black 2 (1.6) 0 (0.0) 2 (2.1) 0 (0.0)
Other 1 (0.8) 3 (3.4) 1 (1.1) 0 (0.0)
BMI (kg/m2) 30.3 ± 5.2 30.1 ± 5.0 30.8 ± 5.8 30.0 ± 4.7
A1C (%) 7.9 ± 1.0 7.9 ± 1.0 7.7 ± 1.0 7.5 ± 1.1
FPG (mmol/l) 9.1 ± 3.3 8.6 ± 2.7 8.3 ± 2.9 8.9 ± 3.6
Duration of T2DM (years) 15.9 ± 9.2 15.2 ± 9.8 17.1 ± 8.6 19.6 ± 9.9
Current antidiabetic therapy
None 4 (3.3) 4 (4.5) 2 (2.1) 0 (0.0)
Any 118 (96.7) 85 (95.5) 92 (97.9) 64 (100)
Insulin monotherapy 77 (63.1) 47 (52.8) 68 (72.3) 44 (68.8)
Insulin and OAD 12 (9.8) 15 (16.9) 10 (10.6) 8 (12.5)
OAD monotherapy 23 (18.9) 21 (23.6) 13 (13.8) 9 (14.1)
OAD combination therapy 6 (4.9) 2 (2.2) 1 (1.1) 3 (4.7)